BMY.SW Bristol-Myers Squibb (SIX) CHF42.54 16 Feb 2026: intraday bounce possible

BMY.SW stock opened the intraday session at CHF42.54 after a -4.40% drop from yesterday’s close, setting a clear oversold bounce setup on the SIX (Switzerland) tape. Volume is light at 500 shares but relative volume is elevated at 22.73x, which signals concentrated trading interest. Traders should treat moves as short-term reaction, watch risk controls, and compare bounce targets against the year high CHF44.75 and previous close CHF44.50.

Intraday technical snapshot: BMY.SW stock oversold bounce

Price action shows BMY.SW stock at CHF42.54, down CHF1.96 on the session. Momentum indicators show MACD histogram at -0.07 and ADX at 100.00, indicating a strong directional trend. ATR is 0.15 CHF, while Keltner channel suggests short-term resistance near CHF43.30 and support near CHF42.69. For intraday bounce trades, use tight stops given the strong trend signals and low average volume backdrop.

Fundamentals and valuation context for BMY.SW stock

Bristol-Myers Squibb (BMY.SW) trades at PE 15.81 with EPS CHF2.69, and a dividend yield near 3.50%. Key metrics show free cash flow yield 23.53% and debt to equity 3.45, signalling leverage pressure but strong cash conversion. Versus the Healthcare sector average PE 33.70, BMY.SW stock looks cheaper on earnings. These fundamentals support a measured bounce view rather than a full trend reversal.

Catalysts, earnings timetable and sector influence

Upcoming earnings are scheduled for 30 Apr 2026, a headline catalyst for BMY.SW stock. Near-term moves may also respond to trial readouts, regulatory updates, and broader Healthcare sector flows. The Swiss Healthcare sector is up 0.29% intraday; relative sector strength could fuel an oversold bounce if positive headlines emerge. See market component lists for context Investing US 500 components.

Meyka stock grade and model forecast for BMY.SW stock

Meyka AI rates BMY.SW with a score out of 100: 73.30/100 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month price of CHF39.34, versus the current CHF42.54, implying -7.51% downside. Forecasts are model-based projections and not guarantees. For an internal reference see our BMY.SW stock page Meyka BMY.SW.

Trading plan: oversold bounce strategy for BMY.SW stock

A tactical intraday plan: consider entering on a confirmed reversal above CHF43.20 with stop-loss under CHF42.00 to limit risk. First profit target is prior close CHF44.50 (≈ 4.61% upside), stretch target CHF46.00 (≈ 8.13% upside). If price breaks below CHF42.54 with volume, step aside — downside tied to the Meyka forecast at CHF39.34. Keep position sizes small given the high relative volume and ADX strength.

Risks and watch‑items for BMY.SW stock

Primary risks are clinical trial setbacks, patent/legal outcomes, and high net leverage. Financial ratios show debt to market cap near 0.94 and payout ratio 72.54%, which can constrain flexibility. Intraday volatility could accelerate on headline surprises. Monitor order flow, block trades, and Healthcare sector momentum for early signals that an oversold bounce will sustain.

Final Thoughts

Key takeaways for BMY.SW stock: the intraday drop to CHF42.54 creates a classic oversold bounce setup, with concentrated volume (500 shares) and high relative volume (22.73x) that can fuel short-term mean reversion. Short-term targets: CHF44.50 (first) and CHF46.00 (stretch), with a protective stop below CHF42.00. On fundamentals, the stock trades at PE 15.81 and yields roughly 3.50%, cheaper than the Healthcare sector PE 33.70, which supports tactical buying on strength. Meyka AI’s forecast model projects CHF39.34, implying -7.51% versus the current price; use that as a downside anchor. These forecasts are model-based projections and not guarantees. We present this as data-driven intraday analysis from Meyka AI, an AI-powered market analysis platform; manage risk and size positions for short-duration trades only.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.